港股異動 | 比亞迪股份(1211.HK)漲5.8% 刀片電池將擴產疊加機構唱好
格隆匯6月5日丨比亞迪股份(1211.HK)現報51港元,漲幅5.81%,最新總市值1686億港元;公司A股現報61.6元,漲幅2.48%。目前已有多家國際品牌與比亞迪洽談“刀片電池”合作事宜,鑑於市場反饋高於預期,比亞迪已決定着手擴大重慶弗迪“刀片電池”生產線,從目前年產能6GWh擴充至今年年底的13GWh以上。此外,摩通研報指,將公司目標價由36港元調高至66港元,評級由“減持”升至“增持”,並上調比亞迪2020至2022年的盈利預期2至15%,主要反映外部電池銷售的增長。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.